MDPV
3,4-methylenedioxypyrovalerone
Viewing r1 — Apr 25, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
MDPV (3,4-methylenedioxypyrovalerone) is a synthetic stimulant of the pyrrolidinophenone class. It is a structural analog of pyrovalerone, approximately ten-fold more potent than cocaine in animal models.[1] MDPV is a dopamine and norepinephrine reuptake inhibitor, producing its effects by blocking the clearance of these neurotransmitters from the synapse.[2]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
cocaine, methylphenidate, alpha-PVP +1 morecocaine, methylphenidate, alpha-PVP, MDPHP show less
Synthesized at Boehringer Ingelheim in 1969 and patented as a stimulant, MDPV was never advanced into clinical development.[3] It appeared on recreational drug markets around 2006 and became the dominant active ingredient in "bath salts" products during the 2010–2012 emergency surge.[4] MDPV is Schedule I in the United States and controlled in most jurisdictions worldwide.[5]
Subjective effects include intense euphoria, psychomotor stimulation, wakefulness, heightened motivation, and compulsive redosing. The experience is defined by raw dopaminergic drive — a relentless, focused stimulation without the empathogenic warmth of serotonergic cathinones, tilting rapidly toward paranoid dysphoria with repeated doses.[6] Compulsive redosing, anxiety, paranoid ideation, and insomnia are characteristic unsought effects.
MDPV carries extreme abuse liability and high acute toxicity — multiple fatalities are documented, including one at a blood concentration far below the typical recreational range.[3] Acute psychosis occurs in 26–40% of emergency presentations,[7] cardiovascular collapse and organ failure appear in severe cases,[8] and tolerance develops within hours via transporter downregulation.[9] No clinical trials or human pharmacokinetic studies have been conducted.
History[edit]
Discovery
MDPV was synthesized by chemists at Boehringer Ingelheim in 1969 and patented as a central nervous system stimulant (US Patent 3478050).[3] The compound was designed as a modification of pyrovalerone, an appetite suppressant briefly marketed in France, with a methylenedioxy group replacing the methyl substituent on the aromatic ring.[10] Despite showing stimulant activity, MDPV was never advanced into clinical trials, and it remained an obscure patent entry for over three decades.
Emergence and the bath salts crisis
MDPV appeared in online drug communities around 2004–2005 and entered European illicit markets by 2006.[3] Between 2010 and 2012, products labeled "bath salts" or "plant food" containing MDPV flooded US convenience stores and head shops, triggering an explosion of emergency department visits.[11][12] MDPV was identified as the dominant psychoactive ingredient in the majority of analyzed bath salts products during this period.
Scheduling and decline
The US Drug Enforcement Administration placed MDPV in Schedule I via emergency order in October 2011, alongside mephedrone and methylone.[5] The United Kingdom had already classified it as Class B in July 2010, and most EU member states followed after a 2013 EMCDDA-Europol risk assessment.[13] Following international scheduling, MDPV was largely replaced on recreational markets by structural analogs — notably alpha-pvp and MDPHP — that offered similar effects while evading new controls.[3]
The name "bath salts" was a marketing label, not a description — products were sold in small packets labeled "not for human consumption" to circumvent drug laws. The term became a media shorthand for synthetic cathinone intoxication during 2011–2012, often accompanied by sensationalized reports of extreme behavior. MDPV itself has no widely established street name distinct from the bath salts branding; in drug communities it is typically referred to by its abbreviation.
Chemistry[edit]
Structural class
MDPV belongs to the α-pyrrolidinophenone subclass of synthetic cathinones, itself part of the broader β-keto phenethylamine family. Its structure features a phenyl ring with a β-keto group, a pyrrolidine ring at the α-carbon rather than a simple amine, and an n-propyl side chain. MDPV differs from its parent compound pyrovalerone by replacement of the 4-methyl group on the aromatic ring with a 3,4-methylenedioxy moiety — the same modification found in MDMA and methylone.[10]
Molecular identity
| Molecular formula | C₁₆H₂₁NO₃ |
| Molecular weight | 275.34 g/mol |
The molecule has three structural domains: a 1,3-benzodioxole aromatic system, a ketone bridge at the β-position, and a pyrrolidine nitrogen with an n-propyl chain extending from the α-carbon. The pyrrolidine ring is critical to MDPV's pharmacology — its steric bulk prevents the compound from being transported through the DAT pore, which is why MDPV blocks reuptake without causing monoamine release.[1][2]
Stereochemistry
MDPV has one chirality center at the α-carbon. Recreationally encountered material is a racemic mixture of S and R enantiomers. The S-enantiomer is approximately 100-fold more potent at the dopamine transporter than the R-enantiomer[14] and accounts for essentially all abuse-related pharmacological activity in animal models.
Physical properties
MDPV hydrochloride appears as a white to off-white crystalline powder, though street samples range from grey to brown to yellow-green depending on synthesis impurities. The free base is a brown to yellow-green oil or solid. The hydrochloride salt is soluble in water, methanol, and chloroform.
MDPV exhibits high blood-brain barrier permeability — among the highest of all cathinones tested — which contributes to its rapid onset and high potency in human use.[2]
Pharmacology[edit]
Mechanism of action
MDPV blocks the DAT (DAT) and NET (NET) at very low concentrations while having negligible activity at the SERT — its selectivity for dopamine over serotonin exceeds 800-fold.[1] This makes it one of the most dopamine-selective stimulants identified among recreational drugs.
Unlike amphetamine-type cathinones such as mephedrone and methylone, which force monoamine release from nerve terminals, MDPV works exclusively as a reuptake blocker.[1][2][15] It prevents dopamine and norepinephrine from being cleared out of the synapse, prolonging their action. The pyrrolidine ring is the structural feature responsible — its bulk prevents the molecule from passing through the transporter.
In animal studies, MDPV is at least 10-fold more potent than cocaine at increasing dopamine levels in the brain's reward circuitry and at producing stimulant effects such as increased movement, elevated heart rate, and raised blood pressure.[1]
Pharmacokinetics
No human pharmacokinetic studies have been published. All available data come from rat models.
In rats, MDPV reaches peak blood levels within approximately 13–19 minutes after injection, with peak brain concentrations reached within 30 minutes.[16][17] The drug accumulates in the brain at roughly twice the blood concentration and sustains this ratio for about two hours.[17] Plasma half-life in rats is approximately 80 minutes.[17]
Behavioral effects track with the parent compound's blood levels, not with metabolite levels, confirming that MDPV itself — not its breakdown products — is the active drug.[16][14]
Metabolism
MDPV is broken down in the liver, primarily by cytochrome P450 enzymes. The main pathway is removal of the methylenedioxy group, producing a catechol metabolite that retains dopamine-blocking activity but penetrates the brain poorly.[18][14] Additional pathways include side-chain modification and pyrrolidine ring oxidation.[18]
The major circulating metabolite in blood has much weaker activity at the dopamine transporter and does not contribute meaningfully to stimulant effects.[16] In urine, breakdown products appear at 3–4 times the concentration of the parent drug.[17] No data on drug-drug interactions through liver enzyme inhibition or induction have been published.
Neuroscience[edit]
Where it acts
MDPV's defining neural action is intense dopamine accumulation in the mesolimbic mesolimbic pathway — the circuit connecting the ventral tegmental area to the nucleus accumbens that drives motivation and reward. MDPV powerfully activates this circuit, lowering the threshold for brain reward stimulation at all doses tested in animal models.[1][6][19]
This reward activation exceeds that produced by mephedrone or methylone at equivalent doses. Its concurrent norepinephrine activity predicts significant effects on prefrontal cortex function — consistent with enhanced focus at low doses and cognitive disorganization at high doses.
Why it matters
MDPV maps onto the incentive salience model of addiction: its extreme dopamine selectivity massively amplifies wanting (motivational drive) while modestly affecting liking (hedonic pleasure). This dissociation explains the characteristic pattern of compulsive redosing even as subjective pleasure diminishes with each subsequent dose.[20]
A single exposure produces measurable reorganization of brain connectivity persisting at least 24 hours — increased network clustering and altered communication patterns that outlast the drug's elimination from the body.[21] Rapid tolerance develops through transporter internalization,[9] while repeated exposure is expected to produce sensitization — progressively stronger motivational responses — through lasting changes in reward circuitry.
No human brain imaging studies of MDPV have been performed. Whether MDPV causes direct damage to dopamine neurons — as methamphetamine does — is unknown; its reuptake-blocker mechanism theoretically limits this risk, but no studies have tested this.
Subjective Effects[edit]
MDPV's experiential character is almost entirely dopaminergic stimulation without serotonergic coloring. Where mephedrone or methylone blend stimulation with empathogenic warmth, MDPV produces raw psychomotor drive, euphoria, and compulsive focus. The experience shifts qualitatively across the dose range — lower doses deliver focused energy and motivation, while higher doses or repeated redosing tips rapidly into paranoid dysphoria and agitation. Set and setting modulate psychological content but exert less control over the core stimulant profile than they would with serotonergic substances.
Pharmacologically, MDPV sits closest to alpha-pvp (identical mechanism, similar potency) and occupies the extreme compulsive end of the stimulant spectrum — closer to crack cocaine in its binge-driving profile than to oral amphetamine or methylphenidate. The transition from euphoria to paranoid dysphoria occurs more abruptly and at lower cumulative doses than with most conventional stimulants.
Effect Grid
At common doses (8–14 mg oral), the full MDPV stimulant experience manifests: pronounced euphoria, strong psychomotor stimulation, intense focus and motivation, thought acceleration, wakefulness, and markedly increased energy. Sexual arousal enhancement is frequently reported. Confidence and talkativeness increase substantially.
Physically, tachycardia, elevated blood pressure, diaphoresis (sweating), jaw clenching, and appetite suppression are typical. Body temperature rises and thirst increases. Vasoconstriction may cause cold extremities and difficulty urinating.
Compulsive redosing urges become significant at this range. Sleep is impossible for 4–8 hours. The crash following the acute phase may involve dysphoria, fatigue, and irritability lasting hours to days.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Gustatory hallucination
Restlessness · Pupil dilation · Dry mouth · Heart rate perception changes · Insomnia · Physical fatigue · Respiratory stimulation · Muscle tension · Excessive sweating · Dehydration sensation · Nausea · Temperature dysregulation · Trembling · Involuntary body movements · Headache · Motor control impairment · Sexual arousal enhancement · Diarrhea · Seizure threshold reduction · Vomiting · Tactile hallucination
Heart rate perception changes · Insomnia · Physical fatigue · Respiratory stimulation · Muscle tension · Excessive sweating · Dehydration sensation · Nausea · Trembling · Involuntary body movements · Headache · Motor control impairment · Sexual arousal enhancement · Diarrhea · Seizure threshold reduction · Vomiting · Tactile hallucination
Cognitive dysphoria · Confusion · Thought disorganization · Thought loops · Motivation enhancement · Motivation suppression · Creativity enhancement · Focus enhancement · Thought deceleration · Thought organization · Delusions · Delirium
Thought loops · Motivation enhancement · Motivation suppression · Creativity enhancement · Focus enhancement · Thought deceleration · Thought organization · Delirium
Anhedonia · Dysphoria · Emotional lability · Mania · Empathy enhancement
Empathy enhancement
Social disconnection · Derealization
Timeline
First alerts emerge 15–30 minutes after oral ingestion: a subtle shift in alertness, mild mood brightening, and faint increase in heart rate. Effects may be overlooked at threshold doses.
Stimulation builds noticeably over 15–30 minutes. Euphoria, energy, and focus increase in tandem with rising heart rate and body temperature. Appetite suppression becomes definite.
Maximum stimulation sustained for 1–2 hours. Intense euphoria, psychomotor drive, thought acceleration, and heightened motivation dominate. Cardiovascular effects are at their strongest.
Stimulation remains elevated but euphoria diminishes. Residual focus and wakefulness persist. Anxiety, jaw tension, and restlessness may become more prominent as the hedonic component fades.
Effects gradually decline over 1–1. 5 hours. Residual stimulation, mild dysphoria, and physical tension persist.
Aftereffects range from mild residual stimulation to pronounced dysphoria, fatigue, irritability, and depressed mood. Duration varies enormously — from 2 hours at low doses to 48 hours following heavy use or binges. Sleep quality may remain impaired.
Safety[edit]
- Acute toxicity
- High
- Chronic toxicity
- Moderate
- Withdrawal
- Moderate
- Tolerance buildup
- rapid
- Tolerance reset
- —
- Physical
- Low
- Psychological
- High
- Compulsive redosing
- High
- Dose escalation
- High
- Cross-tol.
- cocaine · methylphenidate · alpha-PVP
Toxicity
Acute toxicity
MDPV produces a severe stimulant toxicity pattern at recreational doses. The most common presentations include rapid heart rate (63% of emergency visits),[11] extreme agitation,[4] high blood pressure (25% of cases),[7] dangerously elevated body temperature, and heavy sweating.[8][17]
Severe complications include muscle breakdown, acute kidney failure, liver damage, and multi-organ failure.[8][22] Seizures, stroke, heart attack, and cardiorespiratory collapse are documented.[4] Excited delirium — a state of extreme agitation, overheating, and cardiovascular instability — carries significant death risk.[4][3] Intravenous use is associated with the most dangerous presentations.[8]
MDPV is not detected by standard urine drug tests. A person can present with severe stimulant toxicity and test negative on routine screens. Laboratory confirmation requires specialized mass spectrometry testing.[4][22]
Fatalities
Multiple deaths from MDPV are confirmed in the medical literature. Blood concentrations in fatal cases have ranged widely — from 39 ng/mL to over 400 ng/mL[23][24] — but one documented death occurred at only 6 ng/mL, far below the typical recreational range, via excited delirium progressing to cardiac arrest.[3]
No lethal dose has been established in humans or controlled animal studies. The 6 ng/mL fatality demonstrates that death can occur through indirect mechanisms — catecholamine surge, overheating, excited delirium — at concentrations far below those typically associated with recreational use.
Heart toxicity
In laboratory models, MDPV produces concentration-dependent slowing of heart rate and disruption of cardiac conduction at high concentrations.[25] Direct interference with cardiac electrical activity is proposed as the mechanism, independent of the stimulant effects on the nervous system.[25]
Psychological Risks
MDPV-induced psychosis is a well-documented and clinically significant risk. Paranoid delusions and hallucinations occur in 26–40% of emergency presentations,[7][11] and the presentation can be indistinguishable from acute schizophrenia.[4]
Unusual perceptual disturbances — including taste and smell hallucinations — have been reported with intravenous use.[22] Shared paranoid delusions between partners using together have been documented.[26]
Psychosis can persist after stopping MDPV, with cases requiring electroconvulsive therapy for resolution.[27] Repeated use is associated with lasting psychiatric effects including hypomania, paranoid ideation, and persistent delusions.[28] Self-harm and suicidal ideation are documented in clinical presentations.[4]
The high rate of psychosis (26–40%) is notable relative to other stimulants and likely reflects MDPV's extreme dopaminergic potency. Psychosis risk increases with dose but is not predictable — severe psychiatric effects can occur at moderate doses.
Tolerance & Dependence
Acute tolerance develops rapidly through downregulation of dopamine transporters at the cell surface.[9][21] Each subsequent dose within a session produces a diminished effect, driving dose escalation and binge patterns. Brain network changes persisting at least 24 hours after a single exposure suggest neuroadaptation extends well beyond the drug's elimination.[21]
Animal studies consistently demonstrate extreme abuse liability: rats self-administer MDPV at all doses tested, escalate intake under extended access at rates comparable to methamphetamine, and show binge-like patterns of use.[6][20] Inhaled MDPV (via e-cigarette model) produces stimulant and reward effects comparable to injection.[29] MDPV addiction has been confirmed as a clinical reality in human injection drug users.[30]
No formal withdrawal characterization exists. By analogy with cocaine and other dopamine-selective stimulants, a crash of low mood, anhedonia, fatigue, and excessive sleep is expected. Cross-tolerance with other dopamine reuptake inhibitors — Cocaine, methylphenidate, alpha-pvp — is expected based on shared mechanism.
Drug Interactions
Stimulant combinations
Combining MDPV with other stimulants (Cocaine, amphetamines, caffeine) is expected to amplify cardiovascular toxicity through additive catecholamine elevation. MDPV and caffeine together produce reinforcement greater than predicted by simple addition,[31] and cardiovascular effects of MDPV-methylone-caffeine mixtures have been directly studied in animals.[32]
Serotonergic combinations
MDPV's negligible serotonin activity makes serotonin syndrome unlikely when MDPV is the sole serotonergic agent. Combinations with MDMA or tramadol carry cardiovascular risk from combined stimulant effects rather than serotonergic excess.inferred Tramadol additionally lowers seizure threshold, compounding MDPV's own documented seizure risk.[4]
Metabolic interactions
MDPV is metabolized by liver enzymes (CYP2C19, CYP2D6, CYP1A2),[18] creating risk of elevated MDPV levels when taken with drugs that inhibit these enzymes. No specific interaction studies exist.
Alcohol
No MDPV-specific data on alcohol interactions have been published. General concerns include masking of cardiovascular distress, impaired temperature regulation, and additive dehydration.
Contraindications
No MDPV-specific contraindication studies exist. The following are based on MDPV's pharmacological profile and documented clinical toxicity:
Absolute:
- Heart conditions — MDPV's potent stimulant effects (rapid heart rate in 63% of presentations, high blood pressure in 25%) and documented heart attacks make any cardiovascular compromise a high-risk setting[4]
- Psychotic disorders — MDPV induces acute psychosis in 26–40% of emergency cases and can trigger persistent psychotic states[7][27]
- Concurrent stimulant use — additive or synergistic cardiovascular toxicity is documented[31][32]
Relative:
- Bipolar disorder — manic episodes documented with cathinone use[28]
- Kidney impairment — MDPV causes acute kidney failure through multiple mechanisms[8][22]
- Liver impairment — liver damage documented; impaired drug clearance expected[8]
- Seizure disorders — seizures documented[4]
- Pregnancy — no safety data; potent stimulant effects present obvious fetal risksinferred
Harm Reduction[edit]
Forms & Identification
MDPV has been sold as crystalline powder in various colors — pure material is white to off-white, while impure batches range from grey to brown to yellow-green. During the bath salts era it was commonly blended with other cathinones or sold as an unlabeled mixture, making identification by appearance alone unreliable.
Standard immunoassay drug tests do not detect MDPV — only mass spectrometry can confirm its presence. Reagent testing can narrow identification but cannot reliably distinguish MDPV from closely related pyrrolidine cathinones such as alpha-pvp or MDPHP.
Guidelines
- Test material with reagent kits before use; confirm identity through analytical services if possible
- Start with the lowest possible dose — MDPV is active at single-milligram quantities and potency varies by batch
- Use a precision milligram scale; volumetric dosing errors with a substance this potent are dangerous
- Set a firm dose limit before the session begins and do not redose — compulsive redosing is the defining risk pattern with MDPV
- Have a sober companion present who understands the drug's profile and the signs of psychiatric deterioration
- Keep ambient temperature comfortable and hydrate steadily but not excessively
- Avoid physical exertion during the experience
- Oral administration produces the most gradual onset and longest duration; insufflation and injection dramatically increase compulsive redosing risk and acute toxicity
Set & Setting
MDPV's dopaminergic dominance makes set and setting less protective than with serotonergic substances — the core stimulant drive is highly reproducible regardless of environment. A calm, controlled setting with trusted companions reduces the risk of paranoid escalation but does not eliminate it.
Avoid situations requiring sustained social performance or physical exertion. Both amplify cardiovascular strain and hyperthermia risk, and the combination of physical activity with MDPV's sympathomimetic effects significantly worsens the acute toxicity profile.
Aftercare & integration. The MDPV comedown is characteristically harsh — expect low mood, fatigue, irritability, and difficulty concentrating for 24–72 hours after use. Sleep is the single most restorative intervention; if insomnia persists, avoid further stimulant use including caffeine and maintain a dark, quiet environment.
Eat regular meals even if appetite is suppressed — the body needs caloric and electrolyte restoration after intense sympathomimetic stress. If paranoid ideation or perceptual disturbances persist beyond 48 hours after last use, seek professional evaluation — persistent MDPV psychosis is documented and may require psychiatric treatment.[27]
Recovery & Support
MDPV addiction is a documented clinical entity.[30] The compulsive redosing pattern that defines MDPV use can escalate rapidly into daily use and binge cycles. If use has become difficult to control or is causing harm to health, relationships, or functioning, professional support is warranted.
No MDPV-specific treatment protocols exist. Treatment approaches for cocaine and methamphetamine dependence — behavioral therapy, contingency management, and structured support — are the closest clinical analogues. SAMHSA's National Helpline (1-800-662-4357) provides free referrals in the United States.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: chest pain, seizure activity, body temperature hot to the touch through clothing, loss of consciousness, uncontrollable agitation, or any sign of psychotic break (paranoid delusions, hallucinations, violent behavior) all require immediate help.
Immediate steps:
- Call emergency services immediately — do not wait to see if symptoms resolve
- Keep the person in a cool environment; apply cool water to skin if overheating
- Do not attempt to physically restrain unless there is immediate danger of self-harm — restraint can worsen overheating and agitation
- If the person is unconscious, place in the recovery position and monitor breathing
- Remove objects that could cause injury
What to tell the dispatcher: Name the substance (MDPV or synthetic cathinone/bath salts), approximate amount and time of use, and current symptoms — especially body temperature, heart rate, and mental state. Good Samaritan laws in many jurisdictions protect callers who report drug emergencies.
No reversal agent exists for MDPV overdose. Hospital treatment is supportive: sedation for agitation, cooling for overheating, and monitoring of heart, kidney, and liver function.[33]
Legal Status[edit]
MDPV is a controlled substance in most major jurisdictions worldwide. Following explosive growth in emergency presentations between 2010 and 2012, regulatory responses were rapid: the United States, United Kingdom, Canada, and Australia all moved to schedule MDPV within a three-year window, and EU member states followed after the 2013 EMCDDA-Europol joint risk assessment.[13]
The scheduling rationale across jurisdictions centers on high potential for abuse, absence of any accepted medical use, and lack of accepted safety data for use under medical supervision.[5]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule I (Controlled Substances Act) | Emergency scheduling October 2011; permanent Schedule I 2012[5] |
| United Kingdom | Class B (Misuse of Drugs Act 1971) | Classified July 2010citation needed |
| Canada | Schedule I (CDSA) | Controlled since September 26, 2012citation needed |
| Australia (WA) | Schedule 9 (Poisons Act 1964) | Prohibited since February 11, 2012citation needed |
| Australia (NSW) | Schedule 9 (SUSP) | Prohibited since September 2013citation needed |
| European Union | Controlled in most member states | EMCDDA-Europol joint report December 2013; risk assessment led to member state scheduling[13] |
Structural analogs of MDPV — including alpha-pvp, MDPHP, and other pyrrolidine cathinones — may fall under analog scheduling provisions in jurisdictions that maintain such frameworks. The proliferation of MDPV analogs following its scheduling illustrates the limitations of compound-specific scheduling for synthetic drug classes.
references
- [1] ^abcdefBaumann MH, Partilla JS, Lehner KR, Thorndike EB, Hoffman AF, Holy M, Rothman RB, Goldberg SR, Lupica CR, Sitte HH, Brandt SD, Tella SR, Cozzi NV, Schindler CW (2013) Powerful cocaine-like actions of 3,4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive 'bath salts' products — Neuropsychopharmacology doi:10.1038/npp.2012.204
- [2] ^abcdSimmler LD, Buser TA, Donzelli M, et al. (2012) Pharmacological characterization of designer cathinones in vitro — British Journal of Pharmacology doi:10.1111/j.1476-5381.2012.02145.x
- [3]
- [4]
- [5]
- [6] ^abcWatterson LR, Kufahl PR, Nemirovsky NE, Sewalia K, Grabenauer M, Thomas BF, Marusich JA, Wegner S, Olive MF (2014) Potent rewarding and reinforcing effects of the synthetic cathinone 3,4-methylenedioxypyrovalerone (MDPV) — Addiction Biology doi:10.1111/j.1369-1600.2012.00474.x